Corcept Finds Hypercortisolism in 27% of Resistant Hypertension Patients
Event summary
- Corcept presented MOMENTUM trial data at ACC 2026, showing 27.3% of resistant hypertension patients had hypercortisolism.
- The trial screened 1,086 patients across 50 US sites, using a 1-mg dexamethasone suppression test.
- Findings align with Corcept’s CATALYST trial, which found 23.8% hypercortisolism prevalence in difficult-to-control type 2 diabetes patients.
- Corcept’s Lifyorli™ received FDA approval in 2026 for platinum-resistant ovarian cancer.
The big picture
Corcept’s MOMENTUM trial underscores the underdiagnosed role of hypercortisolism in resistant hypertension, a condition affecting millions. The findings could reshape treatment paradigms, particularly as Corcept seeks to broaden the clinical utility of its cortisol modulators. With Lifyorli’s recent approval, the company is positioning itself at the intersection of endocrinology and oncology, where precision medicine is increasingly critical.
What we're watching
- Diagnostic Adoption
- Whether physicians will increase screening for hypercortisolism in resistant hypertension patients following these findings.
- Therapeutic Expansion
- How Corcept leverages these data to expand indications for its cortisol-modulating drugs beyond Cushing’s syndrome and oncology.
- Competitive Positioning
- The pace at which Corcept can differentiate itself in the endocrine and metabolic disorder space amid growing awareness of hypercortisolism.